Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Drug Synthesis. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN102558098A details a one-pot synthesis for EGFR inhibitor intermediates, offering significant cost reduction in API manufacturing and improved supply chain reliability.
Novel one-pot method replaces Pd catalysis for EGFR inhibitor intermediates, offering cost-effective scale-up and high purity for pharma supply chains.
Patent CN113636973B reveals a green industrial method for Palbociclib intermediates, offering high purity, cost reduction, and scalable manufacturing for global supply chains.
Patent CN1247573C reveals a high-yield route for CDK inhibitor intermediates, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturers.
Novel patent CN108467388A details improved Afatinib synthesis avoiding cis-trans isomers, ensuring high purity and supply chain stability for pharmaceutical manufacturing.
Patent CN113801859A details high-efficiency carbonyl reductase mutants for chiral alcohol synthesis, offering superior stereoselectivity and cost reduction in pharmaceutical manufacturing.
Patent CN114262290B reveals silver-catalyzed synthesis for high-purity heterocyclic compounds. Offers significant cost reduction and supply chain reliability for pharmaceutical intermediate manufacturing partners.
Patent CN107011134B reveals a streamlined lithiation-acetylation route for 2-fluoro-5-bromoacetophenone, offering significant cost reduction in API manufacturing and enhanced supply chain reliability.
Patent CN104829655A reveals novel synthesis for anticancer intermediates. Offers scalable routes and purity advantages for pharmaceutical supply chains.
Patent CN102020601B details a novel zinc-mediated cyclization for N-arylindoles. Discover cost-effective manufacturing and scalable supply chain solutions for high-purity intermediates.
Patent CN112041298A details a safe, efficient route for aromatic nitriles via Willgerodt rearrangement. Reduces sulfur impurities and avoids toxic cyanides for pharma intermediates.
Novel method for 4-aminoazaindole ketones via rearrangement and oxidation-reduction. Offers mild conditions and high purity for drug discovery.
Patent CN108823179A reveals high-efficiency transaminase mutant for R-3-aminobutanol, offering significant cost reduction and supply chain reliability for pharmaceutical intermediate manufacturing.
Patent CN112442474B reveals a robust Fusarium oxysporum lactamase for optically pure (-) gamma-lactam production, offering superior stability and cost-effective manufacturing solutions.
Patent CN113831242A reveals a room-temperature synthesis route for Dolutegravir intermediates, offering significant cost reduction and supply chain reliability for global pharmaceutical manufacturers.
Patent CN1675165A discloses a novel route for 1-(acyloxy)-alkyl carbamates of GABA analogs. Enhances bioavailability and simplifies manufacturing for reliable pharmaceutical intermediates supply.
Patent CN103772277B details a prodrug synthesis method offering high purity and targeted delivery for oncology applications.
Patent CN115353519A reveals a novel IBX oxidation route for BTK inhibitor intermediates, offering >99.5% purity and eliminating costly column chromatography for scalable manufacturing.
Novel bromination process for 6-bromo-2-chloro-8-cyclopentyl-5-methyl-pyrido[2,3-d]pyrimidin-7(8H)-one ensures high yield and low impurities for reliable supply chain.
Patent CN102115485A discloses N4-modified cytarabine prodrugs enhancing bioavailability and organ specificity for reliable pharmaceutical intermediate supply chains.